January 2024 in “Journal of dermatology and skin science” In this study, researchers found that applying topical aprepitant, which blocks substance P receptors, significantly reduced facial dermatitis and hair loss in rats experiencing erlotinib-induced skin side effects, highlighting the neurogenic inflammation's role and the protective effect of ROS inhibition.
March 2009 in “Dermatology Online Journal” This study reports that blocking the epidermal growth factor receptor in cancer treatments can lead to changes in hair growth and create a "wavy" hair phenotype in some patients.
87 citations
,
March 2013 in “Expert Review of Anticancer Therapy” This article summarizes dermatologic adverse events in patients treated with afatinib in clinical trials and discusses strategies for managing these side effects, without providing new clinical results.
7 citations
,
May 2014 in “Clinical practice” This article reviews drug-induced hair and nail disorders and discusses their clinical recognition, underlying mechanisms, and potential treatment strategies, without presenting new research findings.
2 citations
,
October 2018 in “Springer eBooks” Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.